Lexaria Bioscience (LEXX) Net Cash Flow (2010 - 2026)

Lexaria Bioscience has disclosed Net Cash Flow across 17 years of filings, most recently posting $826273.0 for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $826273.0, up 154.57% year-over-year; the trailing twelve-month figure through Feb 2026 was -$1.4 million (down 175.42% YoY), and the FY2025 annual result was -$4.6 million, down 189.93% from the prior year.
• Net Cash Flow came in at $826273.0 for Q1 2026 at Lexaria Bioscience, down from $2.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $3.8 million in Q2 2024 to a low of -$2.8 million in Q3 2025.
• The 5-year median for Net Cash Flow is -$1.3 million (2023), against an average of -$264628.6.
• Across the five-year window, Net Cash Flow jumped 3570.48% in 2024 and plunged 154.54% in 2025, its largest moves.
• Lexaria Bioscience's Net Cash Flow stood at -$1.3 million in 2022, then surged by 146.69% to $597691.0 in 2023, then jumped by 164.61% to $1.6 million in 2024, then surged by 57.12% to $2.5 million in 2025, then slumped by 66.75% to $826273.0 in 2026.
• The last three Net Cash Flow figures came in at $826273.0 (Q1 2026), $2.5 million (Q4 2025), and -$2.8 million (Q3 2025), per Business Quant data.